2272: Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort

Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation.

Several bDMARDs and tsDMARDs target different key players in the immune-regulatory pathways, including cytokines, JAK, T cells, and B cells. These molecules enable the achievement of remission or LDA in the majority of patients. However, about 20% to 40% of patients fail to achieve remission, and a smaller percentage, recognized as (multi-drug resistance) MDR-RA, fail several bDMARDs and tsDMARDS. In this subset of severe and multi-resistant patients, the combination of a TNFi and a JAKi might be a promising approach, despite not risk-free.

Methods: We performed a descriptive study of patients from the RA UCLouvain Brussels Cohort, who received a combination of TNFi and JAKi. Disease activity trajectory and tolerability, as well as different therapeutic agents received over time, were recorded.

Results: We report five patients (3F, 2M). They received a combination therapy after a median time of 184 months (IQR 116) from diagnosis. The demographic and clinical features for each patient are reported in Table 1. Figure 1 shows disease activity at the moment of each b/tsDMARDs discontinuation (A), reason for discontinuation (B), and the sequence of the b/tsDMARDs (C) for each patient. All of these pts were refractory to 7 bDMARDs and to 2 JAKi. Of note, all the patients received csDMARDs alongside b/tsDMARDs. Variable-dose glucocorticoids have been part of the therapeutic strategy in combination with standard therapy. None of the patients suffered from major adverse events due to b/tsDMARDs as severe infection. All the patients were treated with a TNFi (infliximab or etanercept) associated with a JAKi (Upatacitinib or Filgotinib). Three patients had a minimum follow-up time of 3 months after the combination and then a second evaluation. Pt 1 achieved a persistent remission state up to 3 years of follow-up. We observed a significant decrease in disease activity in two patients, reaching disease remission. None of the patients developed major side effects, including severe infection or hospitalisation, in the observation period.

Conclusion: Our preliminary results indicate that a combination therapy of a TNFi and a JAKi provided good clinical results without safety concerns. In severe and multi-resistant patients, when all classical approach fails to reach a good disease control, the combination therapy could be an option. As infection is the major risk for those patients, a b/tsDMARDs combination should be restricted to young patients with a low infection risk and after adequate vaccinations.